Clinical trial
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
NCT02916979 is registered in ClinicalTrials.gov with Dartmouth-Hitchcock Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 6, 2016
- Completion date
- February 11, 2022
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
leukemia, lymphoid, leukemia, myeloid, lymphoma, malignant, multiple myeloma, myelodysplastic syndromes, myelofibrosis, waldenstrom macroglobulinemia